GlassScriptPhysician profile
Malay K Dey
NPI 1104807155
$16,103.81
in general payments reported to CMS, 2019-2025
49 companies · $3,195 in 2025
The $3,195 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,603 · 2020: $1,028 · 2021: $2,139 · 2022: $2,457 · 2023: $2,535 · 2024: $3,147 · 2025: $3,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,783 · Education: $92.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,783.23 |
| Education | $92.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,436.19 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,616.39 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $1,173.93 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,038.99 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $986.99 | 2019-2025 | |
| Qol Medical, LLC | $914.14 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $871.52 | 2022-2025 | |
| Celgene Corporation | $510.85 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $452.19 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $390.21 | 2019-2025 | Epclusa |
| Redhill Biopharma INC. | $339.12 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Intercept Pharmaceuticals, INC. | $233.03 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $211.95 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $203.61 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $186.51 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $176.46 | 2024-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $165.74 | 2019-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $163.49 | 2025 | Voquezna |
| Medtronic, INC. | $148.71 | 2021-2024 | Valleylab Ft10 |
| Ardelyx, INC. | $138.17 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $137.93 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $132.16 | 2021-2023 | |
| Braintree Laboratories, INC. | $130.61 | 2022-2025 | Suflave, Sutab |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Romark Laboratories, Lc | $102.21 | 2019-2020 | |
| Vivus LLC | $95.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $88.69 | 2019-2022 | |
| Shionogi INC | $88.53 | 2019 | |
| Organon LLC | $82.41 | 2023-2025 | Hadlima, Renflexis |
| Ironwood Pharmaceuticals, INC | $74.75 | 2021-2023 | Linzess |
| Aimmune Therapeutics, INC. | $74.06 | 2024-2025 | Vowst, Zenpep |
| Ethicon US, LLC | $73.99 | 2020-2021 | |
| Ucb, INC. | $61.78 | 2019-2020 | |
| Novo Nordisk INC | $55.84 | 2025 | Wegovy |
| Evoke Pharma, INC. | $55.14 | 2023-2025 | Gimoti |
| Tersera Therapeutics LLC | $40.74 | 2021-2022 | |
| Alfasigma USA, INC. | $38.59 | 2020 | |
| Celltrion USA INC. | $35.13 | 2023-2024 | Vegzelma, Yuflyma |
| Amgen INC. | $33.46 | 2025 | Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.56 | 2023-2024 | Cyltezo |
| Lucid Diagnostics INC. | $32.35 | 2022-2024 | |
| Dova Pharmaceuticals | $28.86 | 2019 | |
| Azurity Pharmaceuticals, INC. | $25.99 | 2025 | Suflave |
| Alnylam Pharmaceuticals INC. | $22.12 | 2021 | |
| Fresenius Kabi USA, LLC | $20.19 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $17.92 | 2023 | Terlivaz |
| Shire North American Group INC | $16.16 | 2019 | |
| Mylan Institutional INC. | $14.85 | 2023 | Hulio |
| Micro-Tech Endoscopy USA, INC. | $8.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malay Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.